{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:30:39Z","timestamp":1769005839614,"version":"3.49.0"},"reference-count":34,"publisher":"Radiation Research Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiation Research"],"published-print":{"date-parts":[[2019,5,16]]},"DOI":"10.1667\/rr15404.1","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T16:43:22Z","timestamp":1558025002000},"page":"231","source":"Crossref","is-referenced-by-count":11,"title":["DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo"],"prefix":"10.1667","volume":"192","author":[{"given":"Katherine L.","family":"Morel","sequence":"first","affiliation":[{"name":"Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca J.","family":"Ormsby","sequence":"additional","affiliation":[{"name":"Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Flinders University and SA Pathology, Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela J.","family":"Sykes","sequence":"additional","affiliation":[{"name":"Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1243","reference":[{"key":"1","unstructured":"PG Prasanna, HB Stone, RS Wong, et al.  \"Transl Cancer Res.\"  1, \"Normal tissue protection for improving radiotherapy: Where are the gaps?\" 35 (2012)"},{"key":"7","doi-asserted-by":"crossref","unstructured":"JR Kouvaris, VE Kouloulias, LJ. Vlahos,  \"Oncologist.\"  12, \"Amifostine: the first selective-target and broad-spectrum radioprotector.\" 738 (2007)","DOI":"10.1634\/theoncologist.12-6-738"},{"key":"2","doi-asserted-by":"crossref","unstructured":"HB Stone, CN Coleman, MS Anscher, et al.  \"Lancet Oncol.\"  4, \"Effects of radiation on normal tissue: consequences and mechanisms.\" 529 (2003)","DOI":"10.1016\/S1470-2045(03)01191-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"MZ Kamran, A Ranjan, N Kaur, et al.  \"Med Res Rev.\"  36, \"Radioprotective Agents: Strategies and Translational Advances.\" 461 (2016)","DOI":"10.1002\/med.21386"},{"key":"4","doi-asserted-by":"crossref","unstructured":"K Mishra  and G. Alsbeih  \"3 Biotech.\"  7, \"Appraisal of biochemical classes of radioprotectors: evidence, current status and guidelines for future development.\" 292 (2017)","DOI":"10.1007\/s13205-017-0925-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"B Oronsky, S Goyal, MM Kim, et al.  \"Transl Oncol.\"  11, \"A review of clinical radioprotection and chemoprotection for oral mucositis.\" 771 (2018)","DOI":"10.1016\/j.tranon.2018.03.014"},{"key":"6","doi-asserted-by":"crossref","unstructured":"AN Demiral, O Yerebakan, V Simsir, et al.  \"Jpn J Clin Oncol.\"  32, \"Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report.\" 477 (2002)","DOI":"10.1093\/jjco\/hyf095"},{"key":"8","doi-asserted-by":"crossref","unstructured":"VB Mathema, YS Koh, BC Thakuri, et al.  \"Inflammation.\"  35, \"Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities.\" 560 (2012)","DOI":"10.1007\/s10753-011-9346-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"MS Mendonca, H Chin-Sinex, J Gomez-Millan, et al.  \"Radiat Res.\"  168, \"Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair.\" 689 (2007)","DOI":"10.1667\/RR1128.1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Y Sun, DK St Clair, F Fang, et al.  \"Mol Cancer Ther.\"  6, \"The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.\" 2477 (2007)","DOI":"10.1158\/1535-7163.MCT-07-0186"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Y Sun, DK St Clair, Y Xu, et al.  \"Cancer Res.\"  70, \"A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells.\" 2880 (2010)","DOI":"10.1158\/0008-5472.CAN-09-4572"},{"key":"12","doi-asserted-by":"crossref","unstructured":"C Watson, DA Miller, H Chin-Sinex, et al.  \"Radiat Res.\"  171, \"Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells.\" 389 (2009)","DOI":"10.1667\/RR1394.1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"MS Mendonca, WT Turchan, ME Alpuche, et al.  \"Free Radic Biol Med.\"  112, \"DMAPT inhibits NF-kappaB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo.\" 318 (2017)","DOI":"10.1016\/j.freeradbiomed.2017.08.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"NC Estabrook, H Chin-Sinex, AJ Borgmann, et al.  \"Free Radic Biol Med.\"  51, \"Inhibition of NF-kappaB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays.\" 2249 (2011)","DOI":"10.1016\/j.freeradbiomed.2011.09.029"},{"key":"15","doi-asserted-by":"crossref","unstructured":"KL Morel, RJ Ormsby, E Bezak, et al.  \"Radiat Res.\"  187, \"Parthenolide selectively sensitizes prostate tumor tissue to radiotherapy while protecting healthy tissues in vivo.\" 501 (2017)","DOI":"10.1667\/RR14710.1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Y Xu, F Fang, S Miriyala, et al.  \"Cancer Res.\"  73, \"KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells.\" 4406 (2013)","DOI":"10.1158\/0008-5472.CAN-12-4297"},{"key":"17","doi-asserted-by":"crossref","unstructured":"A Ghantous, A Sinjab, Z Herceg, et al.  \"Drug Discov Today.\"  18, \"Parthenolide: from plant shoots to cancer roots.\" 894 (2013)","DOI":"10.1016\/j.drudis.2013.05.005"},{"key":"18","doi-asserted-by":"crossref","unstructured":"F Herrera, V Martin, J Rodriguez-Blanco, et al.  \"Biochem Biophys Res Commun.\"  332, \"Intracellular redox state regulation by parthenolide.\" 321 (2005)","DOI":"10.1016\/j.bbrc.2005.04.131"},{"key":"19","doi-asserted-by":"crossref","unstructured":"H Matsumoto, N Hamada, A Takahashi, et al.  \"J Radiat Res.\"  48, \"Vanguards of paradigm shift in radiation biology: radiation-induced adaptive and bystander responses.\" 97 (2007)","DOI":"10.1269\/jrr.06090"},{"key":"20","doi-asserted-by":"crossref","unstructured":"M Nenoi, B Wang, G. Vares,  \"Hum Exp Toxicol.\"  34, \"In vivo radioadaptive response: a review of studies relevant to radiation-induced cancer risk.\" 272 (2015)","DOI":"10.1177\/0960327114537537"},{"key":"21","doi-asserted-by":"crossref","unstructured":"DJ Grdina, JS Murley, RC Miller, et al.  \"Cancer Res.\"  73, \"A survivin-associated adaptive response in radiation therapy.\" 4418 (2013)","DOI":"10.1158\/0008-5472.CAN-12-4640"},{"key":"22","doi-asserted-by":"crossref","unstructured":"ML Guzman, RM Rossi, S Neelakantan, et al.  \"Blood.\"  110, \"An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.\" 4427 (2007)","DOI":"10.1182\/blood-2007-05-090621"},{"key":"23","doi-asserted-by":"crossref","unstructured":"RJ Aukett, JE Burns, AG Greener, et al.  \"Phys Med Biol.\"  50, \"Addendum to the IPEMB code of practice for the determination of absorbed dose for x-rays below 300 kV generating potential (0.035 mm Al-4 mm Cu HVL).\" 2739 (2005)","DOI":"10.1088\/0031-9155\/50\/12\/001"},{"key":"24","doi-asserted-by":"crossref","unstructured":"RJ Aukett, DW Thomas, AW Seaby, et al.  \"Br J Radiol.\"  69, \"Performance characteristics of the Pantak DXT-300 kilovoltage X-ray treatment machine.\" 726 (1996)","DOI":"10.1259\/0007-1285-69-824-726"},{"key":"25","doi-asserted-by":"crossref","unstructured":"RE Mitchel, JS Jackson, SM. Carlisle,  \"Radiat Res.\"  162, \"Upper dose thresholds for radiation-induced adaptive response against cancer in high-dose-exposed, cancer-prone, radiation-sensitive Trp53 heterozygous mice.\" 20 (2004)","DOI":"10.1667\/RR3190"},{"key":"26","doi-asserted-by":"crossref","unstructured":"KL Morel, RJ Ormsby, EL Solly, et al.  \"Clin Exp Metastasis.\"  35, \"Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide.\" 649 (2018)","DOI":"10.1007\/s10585-018-9915-9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"J Buentzel, O Micke, IA Adamietz, et al.  \"Int J Radiat Oncol Biol Phys.\"  64, \"Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.\" 684 (2006)","DOI":"10.1016\/j.ijrobp.2005.08.005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"RM Burnett, KE Craven, P Krishnamurthy, et al.  \"Oncotarget.\"  6, \"Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells.\" 12682 (2015)","DOI":"10.18632\/oncotarget.3707"},{"key":"29","doi-asserted-by":"crossref","unstructured":"A D'Anneo, D Carlisi, M Lauricella, et al.  \"Cell Death Dis.\"  4, \"Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer.\" e891 (2013)","DOI":"10.1038\/cddis.2013.415"},{"key":"30","doi-asserted-by":"crossref","unstructured":"R Shanmugam, P Kusumanchi, H Appaiah, et al.  \"Int J Cancer.\"  128, \"A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species.\" 2481 (2011)","DOI":"10.1002\/ijc.25587"},{"key":"31","doi-asserted-by":"crossref","unstructured":"JM Song, X Qian, P Upadhyayya, et al.  \"Curr Cancer Drug Targets.\"  14, \"Dimethylaminoparthenolide, a water soluble parthenolide, suppresses lung tumorigenesis through down-regulating the STAT3 signaling pathway.\" 59 (2014)","DOI":"10.2174\/15680096113136660108"},{"key":"32","doi-asserted-by":"crossref","unstructured":"MT Yip-Schneider, H Wu, RH Hruban, et al.  \"Pancreas.\"  42, \"Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.\" 160 (2013)","DOI":"10.1097\/MPA.0b013e318254f455"},{"key":"33","doi-asserted-by":"crossref","unstructured":"MT Yip-Schneider, H Wu, V Njoku, et al.  \"Pancreas.\"  37, \"Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.\" e45 (2008)","DOI":"10.1097\/MPA.0b013e318172b4dd"},{"key":"34","doi-asserted-by":"crossref","unstructured":"MT Yip-Schneider, H Wu, K Stantz, et al.  \"BMC Cancer.\"  13, \"Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.\" 194 (2013)","DOI":"10.1186\/1471-2407-13-194"}],"container-title":["Radiation Research"],"original-title":[],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T08:31:11Z","timestamp":1565771471000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/radiation-research\/volume-192\/issue-2\/RR15404.1\/DMAPT-is-an-Effective-Radioprotector-from-Long-Term-Radiation-Induced\/10.1667\/RR15404.1.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1667\/rr15404.1","relation":{},"ISSN":["0033-7587"],"issn-type":[{"value":"0033-7587","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,16]]}}}